People · Operator
Named in public records as an officer, director or promoter · active 2007–2021 · Pharmaceuticals, Biotech / Pharma, Other Technology, Manufacturing, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ardelyx, Inc. | — | Pharmaceuticals | Series D+ | $210.4M | $3.9B | 2010 |
| Auspex Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $82.8M | $951.9M | 2007 |
| Sorbent Therapeutics Inc | — | Pharmaceuticals | Series B | $58.6M | $221.0M | 2011 |
| Arcadia Biosciences, Inc. | — | Biotech / Pharma | Series B | $58.4M | $7.8M | 2008 |
| Surgiquest Inc | — | Other Technology | Series A | $44.4M | $277.4M | 2015 |
| Exela Holdings Inc | — | Pharmaceuticals | Series B | $26.4M | $556.0M | 2015 |
| Genesis Today, Inc. | — | Manufacturing | Series A | $12.0M | $109.9M | 2009 |
| Arcion Therapeutics, Inc. | — | Biotechnology | Series A | $8.2M | $54.2M | 2010 |
David Collier at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Collier on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Arnold Oronsky | 1 | 10 |
| Michael Grey | 1 | 10 |
| David Mott | 1 | 9 |
| James Healy | 1 | 8 |
| Annalisa Jenkins | 1 | 8 |
| Ned Scheetz | 1 | 8 |
| Scott Minick | 1 | 7 |
| Gordon Ringold | 1 | 7 |
| James I. Healy | 1 | 7 |
| Rodney Altman | 1 | 5 |
| Pratik Shah | 1 | 5 |
| James Campbell | 1 | 5 |
| Mark Wong | 1 | 5 |
| Gregory D. Waller | 1 | 4 |
| Jeremy Caldwell | 1 | 4 |
| Thomas Baruch | 1 | 4 |
| Richard Rodgers | 1 | 4 |
| Markus Goebel | 1 | 4 |
| Kerrie Brady | 1 | 3 |
| Samuel Saks | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.